Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-003165
Filing Date
2025-01-14
Accepted
2025-01-14 08:30:08
Documents
5
Period of Report
2025-01-14

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0227578-6k_immuron.htm 6-K 12503
2 IMMURON ANNOUNCES TRAVELAN CLINICAL TRIAL UPDATE ea022757801ex99-1_immuron.htm EX-99.1 30363
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5290
4 GRAPHIC ex99-1_002.jpg GRAPHIC 30675
5 GRAPHIC ex99-1_003.jpg GRAPHIC 10372
  Complete submission text file 0001213900-25-003165.txt   108162
Mailing Address 62 LYGON STREET LEVEL 3 CARLTON, VICTORIA C3 3053
Business Address 62 LYGON STREET LEVEL 3 CARLTON, VICTORIA C3 3053 61 03 9824 5254
Immuron Ltd (Filer) CIK: 0001660046 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 6-K | Act: 34 | File No.: 001-38104 | Film No.: 25527828
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)